A Phase 1 interventional study of Pegcetacoplan in Neovascular Age-Related Macular Degeneration, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 4 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 427th largest by enrollment of the 491 interventional ones that give a count, is one of 32 that started in 2015, is one of 91 in phase 1, and was the 320th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 32 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 5 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects must be:
Exclusion Criteria:
History of treatment for CNV:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 mg of pegcetacoplan 100 μL IVT injection
Drug: Pegcetacoplan
10 mg of pegcetacoplan 100 μL IVT injection
Drug: Pegcetacoplan
20 mg of pegcetacoplan 100 μL IVT injection
Drug: Pegcetacoplan
On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
Also known as: APL-2
Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity
Safety was assessed throughout the study. A TEAE was defined as any AE that started on/after the IVT injection of pegcetacoplan.
Time frame: Day 1 to Day 113
Number of Dose Limiting Toxicities (DLTs)
The occurrence of any of the following AEs were considered DLTs: intraocular inflammation (vitritis or uveitis), endophthalmitis, sustained elevation of intraocular pressure ≥30 millimeters (mm) of mercury, and/or sustained loss of visual acuity ≥15 letters not attributable to the injection procedure or progression of disease.
Time frame: Day 1 to Day 15
Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t])
The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The median AUC(0-t) is presented for each cohort.
Time frame: Predose (screening), postdose Day 3 to Day 113
Median Dose Normalized AUC(0-t)
The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The dose normalized AUC(0-t) was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized AUC(0-t) is presented for each cohort.
Time frame: Predose (screening), postdose Day 3 to Day 113
Maximum Observed Serum Concentration (Cmax)
The median Cmax is presented for each cohort.
Time frame: Predose (screening), postdose Day 3 to Day 113
Median Dose Normalized Cmax
The dose normalized Cmax was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized Cmax is presented for each cohort.
Time frame: Predose (screening), postdose Day 3 to Day 113
Median Time to the Maximum Measured Serum Concentration (Tmax)
The median Tmax is presented for each cohort. If the maximum value occurred at more than 1 time point, Tmax was defined as the first time point with this value.
Time frame: Predose (screening), postdose Day 3 to Day 113
Median Change From Baseline in Visual Acuity for the Study Eye
Best Corrected Visual Acuity (BCVA) letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
Time frame: Day 1 to Day 113
Median Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickness in the Study Eye
Central retinal thickness, central retinal lesion thickness and central subfield thickness were determined using Spectral Domain Optical Coherence Tomography (SD-OCT).
Time frame: Day 1 to Day 113
Median Change From Baseline in Macular Cube Volume in the Study Eye
Macular cube volume was determined using SD-OCT.
Time frame: Day 1 to Day 113
Male and female subjects aged at least 50 years with the presence of an active choroidal neovascular lesion secondary to age-related macular degeneration were recruited to this Phase 1 open-label, single-dose escalation study at 4 study centers in the United States and Australia.
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Started | 3 | 3 | 7 |
| Completed | 3 | 3 | 7 |
| Not completed | 0 | 0 | 0 |
Safety was assessed throughout the study. A TEAE was defined as any AE that started on/after the IVT injection of pegcetacoplan.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| All TEAEs | 2 | 2 | 4 |
| Ocular TEAEs | 1 | 1 | 2 |
| Treatment-related AEs | 0 | 0 | 2 |
| Serious AEs | 0 | 0 | 0 |
| TEAEs leading to discontinuation | 0 | 0 | 0 |
The occurrence of any of the following AEs were considered DLTs: intraocular inflammation (vitritis or uveitis), endophthalmitis, sustained elevation of intraocular pressure ≥30 millimeters (mm) of mercury, and/or sustained loss of visual acuity ≥15 letters not attributable to the injection procedure or progression of disease.
| Number of DLTs | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Number of Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 |
The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The median AUC(0-t) is presented for each cohort.
| micrograms*day/milliliter (μg*day/mL) | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t]) | 11.89 (11.49 to 13.90) | 29.95 (24.27 to 53.59) | 69.53 (55.06 to 86.92) |
The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The dose normalized AUC(0-t) was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized AUC(0-t) is presented for each cohort.
| (μg*day/mL)/respective mg dose | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Median Dose Normalized AUC(0-t) | 2.97 (2.87 to 3.47) | 3.00 (2.43 to 5.36) | 3.48 (2.75 to 4.35) |
The median Cmax is presented for each cohort.
| μg/mL | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) | 0.383 (0.317 to 0.387) | 0.764 (0.596 to 1.610) | 2.140 (1.440 to 3.970) |
The dose normalized Cmax was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized Cmax is presented for each cohort.
| (μg/mL)/respective mg dose | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Median Dose Normalized Cmax | 0.096 (0.079 to 0.097) | 0.076 (0.060 to 0.161) | 0.107 (0.072 to 0.199) |
The median Tmax is presented for each cohort. If the maximum value occurred at more than 1 time point, Tmax was defined as the first time point with this value.
| day | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Median Time to the Maximum Measured Serum Concentration (Tmax) | 14.0 (8.9 to 14.9) | 7.9 (7.0 to 14.9) | 15.0 (6.9 to 16.0) |
Best Corrected Visual Acuity (BCVA) letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
| letters read correctly | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Median Change From Baseline in Visual Acuity for the Study Eye | 1 (0 to 4) | 3 (-9 to 11) | -1 (-4 to 10) |
Central retinal thickness, central retinal lesion thickness and central subfield thickness were determined using Spectral Domain Optical Coherence Tomography (SD-OCT).
| micrometers | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Retinal thickness | -106 (-129 to 71.5) | 5.0 (-109 to 22.0) | 37.5 (-9.5 to 170.5) |
| Retinal lesion thickness | -79.5 (-128 to 64.0) | 2.5 (-104 to 31.5) | 19.0 (-21.5 to 212.0) |
| Central Subfield Thickness | -29.0 (-48.0 to 42.0) | -12.0 (-80.0 to 20.0) | 65.0 (-11.0 to 138.0) |
Macular cube volume was determined using SD-OCT.
| mm^3 | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Median Change From Baseline in Macular Cube Volume in the Study Eye | -0.4 (-2.1 to 0.2) | -0.1 (-0.3 to 0.2) | 0.3 (-0.3 to 0.7) |
Collected over TEAEs were collected from Day 1 up to the final study visit at Day 113 (approximately 16 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Cohort 2 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Cohort 3 | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Eye painEye disorders | 1/3 | 0/3 | 2/7 |
| Retinal haemorrhageEye disorders | 0/3 | 1/3 | 0/7 |
| HordeolumInfections and infestations | 0/3 | 1/3 | 0/7 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 1/3 | 0/7 |
| Skin irritationSkin and subcutaneous tissue disorders | 0/3 | 1/3 | 0/7 |
| HypertensionVascular disorders | 1/3 | 1/3 | 0/7 |
| Foreign body sensation in eyesEye disorders | 0/3 | 0/3 | 1/7 |
| Vision blurredEye disorders | 0/3 | 0/3 | 1/7 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 1/7 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/3 | 1/7 |
The safety set included all subjects who received any amount of study drug.
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Median | 70 (60 to 73) | 79 (74 to 81) | 72 (68 to 93) | 73 (60 to 93) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 5 | 8 |
| Male | 2 | 1 | 2 | 5 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| White | 3 | 3 | 7 | 13 |
| Hispanic or Latino | 0 | 1 | 2 | 3 |
| Non-Hispanic or Latino | 3 | 2 | 5 | 10 |
Ran from Jan 2015 to primary completion in Mar 2016, 13 months.
Results were first posted in Oct 2020, 4 years 6 months after primary completion.
Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 13 months is below that.
Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →